GenoSensor System, showing results of hybridization to biochip (left) and display of data using software (right). Gene amplification and rearrangements have long been known to occur in cancer cells, and the connection between these events and disease outcome is of great interest, especially in light of the relationship between HER-2/neu amplification and a poor breast cancer prognosis. It is with this backdrop that Vysis, a genomic disease management company based in Downer's Grove, Ill., has
 GenoSensor System, showing results of hybridization to biochip (left) and display of data using software (right). |
The PathVysion HER-2/neu DNA probe is not the first of its kind to be offered. However, this kit is unique in that it includes the means to normalize the signal ...
A citizen science game explores how social choices and networks can influence how an illness moves through a population.
View this Issue
Modern DNA synthesis platforms empower researchers to explore the molecular world, from next-generation sequencing to cell and gene therapy development.
An improved chromatography membrane elution method helps scientists achieve higher yields of pure plasmid DNA.
By fine-tuning polishing conditions, scientists attain high titers of infectious lentiviral particles during purification.
Discover a scalable and flexible GMP-compliant workflow for producing plasmid DNA.
Industry-first smart HPLC system to provide authenticated user access verification on onboard touchscreen for superior security.
Setting new standards for intelligent mass detection, sensitivity, and sustainability.
Compact, Powerful, and now Mass Spec-Connected for Superior Analytical Performance
The Wellcome Sanger Institute, Helmholtz Munich, and Parse Biosciences have announced a landmark international collaboration to create a Cancer Plasticity Atlas.
